Ivane Chkhaidze, Medical Director of Iashvili Children’s Hospital, stated on Monday that the protocol for achondroplasia treatment will most likely be available at the beginning of June, noting that the “working group is finalizing the protocol.”
“Prior to introducing a medicine, this step must be taken. Preparation involves both technical aspects and prescribing criteria,” he explained.
Chkhaidze discusses the risks of Vosoritide and why caution is required.
“The drug’s long-term effects are unknown. You can read in any publication that longer studies are needed to know the effect on final height. This is the most critical thing,” he added.
Parents of children with Achondroplasia have been rallying at the Government Administration for over two weeks. They demand Vosoritide injections for their children.